CooperVision has announced that Japan’s Ministry of Health, Labor and Welfare has approved its MiSight® 1 day contact lens, making it the first soft contact lens in the country authorized for myopia correction and control in children.
The decision represents a major milestone in addressing one of Japan’s most pressing eye health challenges. Myopia prevalence among Japanese children is among the highest in the world, affecting 77% of those aged 6–11 and 95% of those aged 12–14. Left unchecked, progressive myopia not only impairs vision but also increases long-term risks of retinal detachment, glaucoma, and other sight-threatening conditions.
MiSight® 1 day incorporates ActivControl® technology, which features treatment and correction zones within the lens design. This dual action both corrects refractive error and slows axial length elongation — the key driver of myopia progression. The product is backed by the longest-running clinical study of any soft contact lens for myopia control, spanning seven years.
"Introducing MiSight® 1 day as an accessible tool to help treat the myopia epidemic among Japanese children has the potential to help prevent longer-term ocular health consequences on a significant scale,” says Jennifer Lambert, Vice President of Myopia Management & Cornea Care at CooperVision. “We look forward to partnering with Japan’s renowned ophthalmology community to fight myopia together.”
With this authorization, MiSight® 1 day is now the only contact lens approved for myopia control in three major markets: Japan, the United States, and China. Commercial launch and distribution details in Japan will be released in the coming weeks.
The decision represents a major milestone in addressing one of Japan’s most pressing eye health challenges. Myopia prevalence among Japanese children is among the highest in the world, affecting 77% of those aged 6–11 and 95% of those aged 12–14. Left unchecked, progressive myopia not only impairs vision but also increases long-term risks of retinal detachment, glaucoma, and other sight-threatening conditions.
MiSight® 1 day incorporates ActivControl® technology, which features treatment and correction zones within the lens design. This dual action both corrects refractive error and slows axial length elongation — the key driver of myopia progression. The product is backed by the longest-running clinical study of any soft contact lens for myopia control, spanning seven years.
"Introducing MiSight® 1 day as an accessible tool to help treat the myopia epidemic among Japanese children has the potential to help prevent longer-term ocular health consequences on a significant scale,” says Jennifer Lambert, Vice President of Myopia Management & Cornea Care at CooperVision. “We look forward to partnering with Japan’s renowned ophthalmology community to fight myopia together.”
With this authorization, MiSight® 1 day is now the only contact lens approved for myopia control in three major markets: Japan, the United States, and China. Commercial launch and distribution details in Japan will be released in the coming weeks.
